PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET
IntroductionThis study aimed to investigate the dynamics of programmed death-ligand 1 (PD-L1) expression, spatial heterogeneity, and binding affinity of FDA-approved anti-PD-L1 antibodies (avelumab and atezolizumab) in gastric cancer. Additionally, we …